Literature DB >> 26935559

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.

Holger Moch1, Antonio L Cubilla2, Peter A Humphrey3, Victor E Reuter4, Thomas M Ulbright5.   

Abstract

UNLABELLED: The fourth edition of the World Health Organization (WHO) classification of urogenital tumours (WHO "blue book"), published in 2016, contains significant revisions. These revisions were performed after consideration by a large international group of pathologists with special expertise in this area. A subgroup of these persons met at the WHO Consensus Conference in Zurich, Switzerland, in 2015 to finalize the revisions. This review summarizes the most significant differences between the newly published classification and the prior version for renal, penile, and testicular tumours. Newly recognized epithelial renal tumours are hereditary leiomyomatosis and renal cell carcinoma (RCC) syndrome-associated RCC, succinate dehydrogenase-deficient RCC, tubulocystic RCC, acquired cystic disease-associated RCC, and clear cell papillary RCC. The WHO/International Society of Urological Pathology renal tumour grading system was recommended, and the definition of renal papillary adenoma was modified. The new WHO classification of penile squamous cell carcinomas is based on the presence of human papillomavirus and defines histologic subtypes accordingly. Germ cell neoplasia in situ (GCNIS) of the testis is the WHO-recommended term for precursor lesions of invasive germ cell tumours, and testicular germ cell tumours are now separated into two fundamentally different groups: those derived from GCNIS and those unrelated to GCNIS. Spermatocytic seminoma has been designated as a spermatocytic tumour and placed within the group of non-GCNIS-related tumours in the 2016 WHO classification. PATIENT
SUMMARY: The 2016 World Health Organization (WHO) classification contains new renal tumour entities. The classification of penile squamous cell carcinomas is based on the presence of human papillomavirus. Germ cell neoplasia in situ of the testis is the WHO-recommended term for precursor lesions of invasive germ cell tumours.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Male genital organs; Urogenital tract; WHO classification

Mesh:

Substances:

Year:  2016        PMID: 26935559     DOI: 10.1016/j.eururo.2016.02.029

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  720 in total

1.  Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.

Authors:  Simone Bertz; S Wach; H Taubert; R Merten; F S Krause; S Schick; O J Ott; E Weigert; O Dworak; C Rödel; R Fietkau; B Wullich; B Keck; A Hartmann
Journal:  Virchows Arch       Date:  2016-07-08       Impact factor: 4.064

2.  Sinonasal Metastatic Renal Cell Carcinoma: A Report of Two Cases with Varied Presentation and a Review of Literature.

Authors:  Pooja Dalakoti; Kailesh Pujary; Balakrishnan Ramaswamy
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-08-24

3.  A rational risk assessment for intravesical recurrence in primary low-grade Ta bladder cancer: A retrospective analysis of 245 cases.

Authors:  Masakazu Akitake; Keijiro Kiyoshima; Akira Yokomizo; Kenichiro Shiga; Hirofumi Koga; Ario Takeuchi; Masaki Shiota; Junichi Inokuchi; Katsunori Tatsugami; Akito Yamaguchi; Masatoshi Eto
Journal:  Mol Clin Oncol       Date:  2018-04-02

4.  Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study).

Authors:  François-Xavier Nouhaud; Jean-Christophe Bernhard; Pierre Bigot; Zine-Eddine Khene; François Audenet; Herve Lang; Sebastien Bergerat; Guillaume Fraisse; Nicolas Grenier; François Cornelis; Cosmina Nedelcu; Sofiane Béjar; Gaëlle Fromont-Hankard; Yves Allory; Véronique Lindner; Virginie Verkarre; Laurent Daniel; Mokrane Yacoub; Jean-Michel Correas; Arnaud Méjean; Nathalie Rioux-Leclercq; Karim Bensalah
Journal:  World J Urol       Date:  2018-05-05       Impact factor: 4.226

Review 5.  Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.

Authors:  Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki
Journal:  World J Urol       Date:  2018-06-01       Impact factor: 4.226

6.  Clinical significance of random bladder biopsy in primary T1 bladder cancer.

Authors:  Masafumi Otsuka; Satoru Taguchi; Tohru Nakagawa; Teppei Morikawa; Shigekatsu Maekawa; Jimpei Miyakawa; Akihiko Matsumoto; Hideyo Miyazaki; Tetsuya Fujimura; Hiroshi Fukuhara; Haruki Kume; Yasuhiko Igawa; Yukio Homma
Journal:  Mol Clin Oncol       Date:  2018-03-08

7.  MicroRNA-183 promotes the proliferation and metastasis of renal cell carcinoma through targeting Dickkopf-related protein 3.

Authors:  Xiao-Long Zhang; Gang Xu; Yi Zhou; Jia-Jun Yan
Journal:  Oncol Lett       Date:  2018-02-08       Impact factor: 2.967

Review 8.  Prognostic impact of PD-1 and its ligands in renal cell carcinoma.

Authors:  Franziska Erlmeier; Wilko Weichert; Andres Jan Schrader; Michael Autenrieth; Arndt Hartmann; Sandra Steffens; Philipp Ivanyi
Journal:  Med Oncol       Date:  2017-04-21       Impact factor: 3.064

9.  The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.

Authors:  Mariana M Cajaiba; Lisa M Dyer; James I Geller; Lawrence J Jennings; David George; Dawn Kirschmann; Stephen M Rohan; Nicholas G Cost; Geetika Khanna; Elizabeth A Mullen; Jeffrey S Dome; Conrad V Fernandez; Elizabeth J Perlman
Journal:  Cancer       Date:  2018-06-15       Impact factor: 6.860

10.  Diagnostic performance of prospectively assigned clear cell Likelihood scores (ccLS) in small renal masses at multiparametric magnetic resonance imaging.

Authors:  Brett A Johnson; Sandy Kim; Ryan L Steinberg; Alberto Diaz de Leon; Ivan Pedrosa; Jeffrey A Cadeddu
Journal:  Urol Oncol       Date:  2019-09-17       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.